gastric cancer
Conditions
Interventions
Group A:oxaliplatin plus capecitabine
Group B:docetaxel plus S-1
Sponsors
Anhui Provincial Tumor Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years; 2. After radical resection of adenocarcinoma of the stomach and gastroesophageal junction confirmed by histology or cytology, according to the AJCC/UICC staging (8th edition) TNM stage of gastric cancer is IIIc stage (T3N3bM0, T4aN3bM0, T4bN3a/N3bM0); 3. ECOG score is 0-1; 4. The organ function level must meet the following requirements: ANC>=1.5x10^9/L, PLT>=85x10^9/L, Hb>=90g/L, serum albumin>=30g/L, TBIL<=1.5xULN, ALT and AST<= 2.5xULN; 5. The operation was performed with D2 lymph node dissection with R0 resection; 6. Female subjects of childbearing age or male subjects whose sexual partners are females of childbearing age should take effective contraceptive measures throughout the treatment period and 6 months after the treatment period; 7. The patients voluntarily joined the study, signed the informed consent form, could take oral chemotherapy drugs, had good compliance, and cooperated with follow-up.
Exclusion criteria
Exclusion criteria: 1. Received chemotherapy or radiotherapy with other drugs during the perioperative period; 2. Patients who have not received chemotherapy for more than 8 weeks after surgery; 3. Patients with severe cardiovascular and cerebrovascular diseases, severe lung diseases (interstitial pneumonia, pulmonary fibrosis, severe emphysema), etc.; 4. Patients with metastases from other sites; 5. Patients with serious complications (intestinal obstruction, liver and kidney insufficiency, cerebrovascular disorder); 6. Pregnant and lactating patients; 7. Patients who are determined in the research to be unsuitable to participate in this clinical trial; 8. Received systemic systemic therapy with Chinese herbal medicines with anti-tumor indications or immunomodulatory drugs (including thymosin, interferon, interleukin, etc.) within 2 weeks before the first administration; 9. Received live attenuated vaccine within 4 weeks prior to the first study; 10. Active autoimmune disease, or known history of primary immunodeficiency; 11. Suffering from active pulmonary tuberculosis; 12. Serious infection with poor clinical control in active stage; 13. Symptomatic congestive heart failure or arrhythmia with poorly controlled symptoms; 14. Hypertension that is still poorly controlled even with standard treatment; 15. Any arterial thromboembolic events, including myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient cerebral ischemic attack, occurred within 6 months before enrollment; 16. History of deep vein thrombosis, pulmonary embolism or any other serious thromboembolism within 3 months before enrollment 17. History of intestinal obstruction or the following diseases: inflammatory bowel disease, or extensive bowel resection, Crohn's disease, ulcerative colitis; 18. Known to have acute or chronic active hepatitis B, HBV DNA exceeding 103copies/ml, or chronic active hepatitis C; 19. History of gastrointestinal perforation or fistula within 6 months prior to inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease free survival; | — |
Countries
China
Contacts
Public ContactHe Yifu
Anhui Provincial Tumor Hospital
Outcome results
None listed